Updated: about 2 months ago
Deadline: 13 Feb 2023

Published: 2023-01-26

Uppsala University is a comprehensive research-intensive university with a strong international standing. Our ultimate goal is to conduct education and research of the highest quality and relevance to make a long-term difference in society. Our most important assets are all the individuals whose curiosity and dedication make Uppsala University one of Sweden’s most exciting workplaces. Uppsala University has over 54,000 students, more than 7,500 employees and a turnover of around SEK 8 billion.

The Department of Immunology, Genetics and Pathology at Uppsala University has a broad research profile with strong research groups focused on cancer, autoimmune and genetic diseases. A fundamental idea at the department is to stimulate translational research and thereby closer interactions between medical research and health care. Research is presently conducted in the following areas: cancer precision medicine, cancer immunotherapy, genomics and neurobiology, molecular tools and functional genomics, neuro-oncology and neurodegeneration and vascular biology. Department activities are also integrated with the units for Oncology, Clinical Genetics, Clinical Immunology, Clinical Pathology, and Hospital Physics at Akademiska sjukhuset, Uppsala. The department has teaching assignments in several education programmes, including Master Programmes, at the Faculty of Medicine, and at the Disciplinary Domain of Science and Technology. The department has a yearly turnover of around SEK 500 million, out of which more than half is made up of external funding. The staff amounts to approximately 345 employees, out of which 100 are PhD-students, and there are in total more than 700 affiliated people. Feel free to read more about the department's activities here:

Read more about our benefits and what it is like to work at Uppsala University

Development of targeted radionuclide therapy using engineered scaffold proteins (affibody molecules, ADAPTs and DARPins). The methodology includes both direct targeting and pretargeting. The work includes development of labelling  chemistry of proteins and peptide nucleic acids with beta-emitting radionuclides, evaluation of the labelled constructs in vitro (stability, binding specificity, affinity, and cellular processing) and in vivo (biodistribution, targeting specificity, radionuclide imaging, dosimetry, experimental therapy). Work might include a supervision of MSc and PhD students. 

PhD degree in medical sciences or radiopharmacy with specialization in development of targeted
radiopharmaceutics. MSc in organic chemistry or biotechnology. FELASA C certificate is a requirement. 

Additional qualifications
Documented experience in work with radiolabelled scaffold proteins (labelling chemistry, in vitro and in vivo studies), as well as experience in development of pretargeting systems are very strong merits 

About the employment
The employment is a permanent position, probationary period may be applied. Scope of employment 20 %. Starting date 2023-02-24. Placement: Uppsala

For further information about the position, please contact: 
Vladimir Tolmachev,

Please submit your application by 13 febuary 2023, UFV-PA 2023/299.

Are you considering moving to Sweden to work at Uppsala University? Find out more about what it´s like to work and live in Sweden.  

Please do not send offers of recruitment or advertising services.

Submit your application through Uppsala University's recruitment system.

Placement: Department of Immunology, Genetics and Pathology

Type of employment: Full time , Permanent position

Pay: Individual salary

Number of positions: 1

Working hours: 20%

Town: Uppsala

County: Uppsala län

Country: Sweden

Union representative: Seko Universitetsklubben

Number of reference: UFV-PA 2023/299

Last application date: 2023-02-13

Apply for position
View or Apply

Similar Positions